Back to top
more

IMab (IMAB)

(Delayed Data from NSDQ)

$1.80 USD

1.80
224,274

0.00 (0.00%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $1.81 +0.01 (0.56%) 4:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks

by Zacks Equity Research

IMab Sponsored ADR (IMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal

by Zacks Equity Research

I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.

I-Mab (IMAB) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

I-Mab (IMAB) recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.

Reata (RETA) Plunges on FDA Concerns for Kidney Failure Drug

by Zacks Equity Research

The FDA raises concerns related to data in Reata's (RETA) NDA seeking approval for bardoxolone for treating Alport syndrome. An advisory committee meeting is scheduled tomorrow.

Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension

by Zacks Equity Research

Amryt (AMYT) is seeking approval for Oleogel-S10 for treating epidermolysis bullosa, a rare genetic skin disorder, in the United States and Europe. The FDA extends the review period for the drug's NDA to reviewnew data submission.

Does IMab Sponsored ADR (IMAB) Have the Potential to Rally 31% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for IMab Sponsored ADR (IMAB) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing

by Zacks Equity Research

Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.

Indrajit Bandyopadhyay headshot

3 Small Biotech Stocks in Focus on World Arthritis Day

by Indrajit Bandyopadhyay

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.

AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy

by Zacks Equity Research

AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.

Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa

by Zacks Equity Research

Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.

Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension

by Zacks Equity Research

Ascendis (ASND) is seeking approval for lonapegsomatropin as a potential treatment of pediatric growth hormone deficiency.

I-Mab (IMAB) Surges: Stock Moves 5.5% Higher

by Zacks Equity Research

I-Mab (IMAB) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Company News for Sep 8, 2020

by Zacks Equity Research

Companies in the news are: IMAB, LMPX, DPW, ANPC

AbbVie Partners With Chinese Biotech for Cancer Candidate

by Zacks Equity Research

AbbVie (ABBV) signs a collaboration agreement with China's I-Mab for developing/commercializing the latter's lemzoparlimab to address various cancer types.